Received Mar 19, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 3 | Unknown | PO / MO |
The patient took dose two and dose three of Vivotif vaccine 24 hours apart instead of 48 hours; Case reference number US-BN-2025-000388 is a spontaneous case report initially received from a pharmacist via Communication (reference number: USBAV25-0618) on 19-Mar-2025 and concerns a female patient of unspecified age. The patient's relevant medical history and concomitant medications were not provided. On an unspecified date, the patient took first dose of Vivotif vaccine (batch number: unknown) at an unknown dose, orally for unknown indication. On 18-Mar-2025, unknown of time after first dose of Vivotif vaccine, the patient took second dose of Vivotif vaccine (batch number: unknown) at an unknown dose, orally. On 19-Mar-2025, one day after the first dose as reported 24 hours apart instead of 48 hours, the patient took third dose of Vivotif vaccine (batch number: unknown) at an unknown dose, orally (explicitly coded as 'Inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif vaccine. Non-significant follow up was downloaded from VAERS on 04-Aug-2025 included new reference number.; Reporter's Comments: A female patient of unspecified age took the third dose of Vivotif vaccine one day after the first dose, as reported 24 hours apart instead of 48 hours, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's relevant medical history and concomitant medications were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A female patient of unspecified age took the third dose of Vivotif vaccine one day after the first dose, as reported 24 hours apart instead of 48 hours, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's relevant medical history and concomitant medications were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.